Skip to main content
. 2018 Jan 12;9(15):11905–11921. doi: 10.18632/oncotarget.24190

Figure 4. Treatment of testosterone in C2C12 cells.

Figure 4

(A) Differentiated C2C12 cells were treated with different concentrations of testosterone (T) (0, 5 × 10-9, 5 × 10-8, 5 × 10-7 and 5 × 10-6 M) for 24h. (A) Representative Western blots and densitometry quantification of (B) p-mTOR/mTOR and (C) LC3-II/LC3-I. (D) Differentiated C2C12 cells were treated with T (0, 5 × 10-7 M) for 24h. Representative Western blots and densitometry quantification of p62. EIF-5 was used as a control. (E) Ratio of integrated mitochondrial to nuclear DNA number. (F) Normalized ATP production. (G) Representative Western blots and densitometry quantification of plasma membrane GLUT4. Na/K-ATPase served as a loading control of plasma membrane protein. (H) 2-NBDG glucose uptake assay. (I) Insulin-signaling assay. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, vs control; #P < 0.05, ##P < 0.01. n = 6/group. T: testosterone. GLUT4: glucose transporter 4.

HHS Vulnerability Disclosure